A Dose-Escalating Study of Obinutuzumab in Patients With B-lymphocyte Antigen (CD20+) Malignant Disease (GAUGUIN)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Obinutuzumab
Related studies linked through entity extraction aliases.
Related studies linked through entity extraction aliases.